N/A
Completed N=320
Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes
Source: ClinicalTrials.gov NCT00401622 ↗Enrolled (actual)
320
Serious AEs
0.3%
Results posted
Sep 2010
Primary outcomePrimary: Change in A1C From Baseline to Week 52 Between the OneTouch® Ultra®2 and Control BGMS. — -0.35; -0.18 Percentage — p=0.45
Summary
Clinical benefits of the OneTouch® Ultra®2 BGMS versus standard BGMS during 52 weeks of use.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in A1C From Baseline to Week 52 Between the OneTouch® Ultra®2 and Control BGMS. |
-0.35; -0.18 | 0.45 |
| SECONDARY Change in Daily Glycemic Excursions Between the OneTouch® Ultra®2 and Control BGMS. |
102.7; 105.8 | 0.31 |
Eligibility Criteria
Inclusion Criteria:·
- Current diagnosis of type 2 diabetes
- Diagnosed at least 3 months prior to the start of the study but not more than 15 years from the start of the study
- Stable regimen (i.e., no changes in therapeutic regimen) for the past three months
- Baseline HbA1c of 7.0 to 8.9%, inclusive
Exclusion Criteria
- Using insulin
- Using oral agents that target post-prandial hyperglycemia (Note: These medications may be added during the study)
- Known history of anemia or disorders associated with anemia
- Has previously used the devices being tested in the study
Data sourced from ClinicalTrials.gov (NCT00401622). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.